Quotes 5-day view Delayed Nyse
01/19/2021
01/20/2021
01/21/2021
01/22/2021
01/25/2021
Date
55.86(c)
56.93(c)
53.13(c)
55.21(c)
52.23(c)
Last
3 909 795
4 809 581
3 667 897
6 372 787
4 905 958
Volume
+6.22% +1.92% -6.67% +3.91% -5.40% Change
Sales 2020
278 M - -
Net income 2020
-428 M - -
Net Debt 2020
36,9 M - -
P/E ratio 2020
-16,0x
Yield 2020
-
Sales 2021
463 M - -
Net income 2021
-268 M - -
Net Debt 2021
132 M - -
P/E ratio 2021
-32,9x
Yield 2021
-
Capitalization
9 896 M 9 896 M -
EV / Sales 2020
35,7x
EV / Sales 2021
21,6x
Nbr of Employees
1 900
Free-Float
99,1%
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company's products consisted of assays totaling over 1,100 genes that could be used for...
Notations Surperformance© of Invitae Corporation
Trading Rating : Investor Rating :
All news about INVITAE CORPORATION
News in other languages on INVITAE CORPORATION
Analyst Recommendations on INVITAE CORPORATION
Chart INVITAE CORPORATION
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends INVITAE CORPORATION
Short Term Mid-Term Long Term Trends Neutral Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
8
Average target price
51,25 $
Last Close Price
52,23 $
Spread / Highest target
22,5%
Spread / Average Target
-1,88%
Spread / Lowest Target
-21,5%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
